Patients with polycythemia vera enrolled in the REVEAL trial have high symptom burden resulting in substantial physical and emotional quality of life impairment and notable work productivity loss, a study published in conjunction with the 2016 annual meeting of the American Society of Clinical Oncology (ASCO) has shown.1
Despite the profound symptom burden associated with polycythemia vera, historical treatments have not demonstrated an improvement in quality of life. Therefore, researchers sought to describe symptom burden, disease management, and patient-reported outcomes of patients in the REVEAL trial.
The REVEAL study is a multicenter, noninterventional, nonrandomized, prospective, observational study in an adult population of men and women with clinically overt polycythemia vera and are being followed in either community or academic medical centers in the United States.
Among the 1552 evaluable patients, 72.8% reported having moderate to severe symptoms at the time of enrollment. Fatigue, night sweats, early satiety, inactivity, itching, and concentration problems were reported as the most severe symptoms.
Average global health status/quality of life measured using the EORTC QLQ-C30 was 73.2. Functional cognitive, emotional, physical, role, and social subscale scores were 80.7, 80.9, 83.5, 85.0, and 85.7, respectively.
Further analyses of the REVEAL study will evaluate the changes in quality of life over time and may ultimately be used in clinical practice.
1. Grunwald MR, Boccia RV, Moliterno A, et al. Self-reported quality-of-life (QoL) impairment and productivity loss in patients with polycythemia vera (PV) enrolled in the REVEAL study. J Clin Oncol. 2016;34(suppl):Abstr e18561.